Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates

Patients receiving treatment with B-cell-depleting monoclonal antibodies, such as anti-CD20 monoclonal antibodies, such as rituximab and obinutuzumab, either for hematological disease or another diagnosis, such as a rheumatological disease, are at an increased risk for medical complications and mort...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, Petros, Katsigiannis, Athanasios, Papakitsou, Ioanna, Kopidakis, Ioannis, Makraki, Eirini, Milonas, Dimitris, Filippatos, Theodosios D., Sourvinos, George, Papadogiannaki, Marina, Lydaki, Evaggelia, Chamilos, Georgios, Kofteridis, Diamantis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059055/
https://www.ncbi.nlm.nih.gov/pubmed/36992465
http://dx.doi.org/10.3390/v15030756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059055/
https://www.ncbi.nlm.nih.gov/pubmed/36992465
http://dx.doi.org/10.3390/v15030756

Ejemplares similares